BioNTech Operating Income from 2010 to 2025

BNTX Stock

USD 108.49 1.66 1.51%

BioNTech Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit BioNTech SE generates from its operations. View All Fundamentals

Operating Income

First Reported

2018-03-31

Previous Quarter

148.6 M

Current Value

-534.1 M

Quarterly Volatility

1.8 B

Covid

Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Net Interest Income of 446.2 M, Interest Income of 459.5 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 9.02, Dividend Yield of 0.011 or PTB Ratio of 1.41. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.

Build AI portfolio with BioNTech Stock

Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Operating Income Growth Pattern

Below is the plot of the Operating Income of BioNTech SE over the last few years. Operating Income is the amount of profit realized from BioNTech SE operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of BioNTech SE is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. BioNTech's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

BioNTech Operating Income Regression Statistics

	Arithmetic Mean	1,577,875,625
	Coefficient Of Variation	309.37
	Mean Deviation	3,096,343,594
	Median	(61,277,000)
	Standard Deviation	4,881,482,177
	Sample Variance	23828868.2T
	Range	16.6B
	R-Value	0.28
	Mean Square Error	23524347.3T
	R-Squared	0.08
	Significance	0.29
	Slope	287,443,912
	Total Sum of Squares	357433023.6T

BioNTech Operating Income History

	2025	-1.2 B
	2024	-1.3 B
	2023	690.4 M
	2022	12.6 B
	2021	15.3 B
	2020	-82.4 M
	2019	-181.5 M

Other Fundumenentals of BioNTech SE

Non Operating Income Net Other

BioNTech Operating Income component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Long Term Investments	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	0.59	-0.93	0.99	0.93	0.62	0.84	0.78	0.9	0.79	0.95	0.68	0.84	0.7	0.96	0.96	0.86
Total Stockholder Equity	1.0		0.58	-0.94	1.0	0.94	0.58	0.85	0.79	0.88	0.81	0.94	0.65	0.85	0.69	0.96	0.96	0.85
Current Deferred Revenue	0.59	0.58		-0.5	0.56	0.7	0.23	0.69	0.6	0.58	0.62	0.56	0.4	0.69	0.74	0.59	0.56	0.79
Net Debt	-0.93	-0.94	-0.5		-0.95	-0.85	-0.4	-0.77	-0.7	-0.75	-0.74	-0.9	-0.44	-0.78	-0.61	-0.93	-0.92	-0.76
Retained Earnings	0.99	1.0	0.56	-0.95		0.94	0.54	0.87	0.81	0.86	0.83	0.93	0.61	0.87	0.66	0.95	0.95	0.83
Accounts Payable	0.93	0.94	0.7	-0.85	0.94		0.38	0.97	0.94	0.76	0.94	0.81	0.5	0.96	0.71	0.85	0.83	0.88
Net Receivables	0.62	0.58	0.23	-0.4	0.54	0.38		0.19	0.12	0.84	0.11	0.69	0.97	0.19	0.49	0.61	0.65	0.5
Good Will	0.84	0.85	0.69	-0.77	0.87	0.97	0.19		0.98	0.62	0.99	0.69	0.34	1.0	0.58	0.76	0.72	0.79
Short Term Investments	0.78	0.79	0.6	-0.7	0.81	0.94	0.12	0.98		0.53	0.99	0.6	0.26	0.97	0.51	0.67	0.63	0.74
Total Liab	0.9	0.88	0.58	-0.75	0.86	0.76	0.84	0.62	0.53		0.54	0.95	0.89	0.62	0.71	0.93	0.94	0.81
Long Term Investments	0.79	0.81	0.62	-0.74	0.83	0.94	0.11	0.99	0.99	0.54		0.63	0.26	0.99	0.51	0.7	0.67	0.73
Total Current Assets	0.95	0.94	0.56	-0.9	0.93	0.81	0.69	0.69	0.6	0.95	0.63		0.74	0.7	0.69	0.99	1.0	0.81
Short Term Debt	0.68	0.65	0.4	-0.44	0.61	0.5	0.97	0.34	0.26	0.89	0.26	0.74		0.35	0.59	0.68	0.71	0.59
Intangible Assets	0.84	0.85	0.69	-0.78	0.87	0.96	0.19	1.0	0.97	0.62	0.99	0.7	0.35		0.63	0.76	0.73	0.79
Common Stock	0.7	0.69	0.74	-0.61	0.66	0.71	0.49	0.58	0.51	0.71	0.51	0.69	0.59	0.63		0.7	0.69	0.85
Net Invested Capital	0.96	0.96	0.59	-0.93	0.95	0.85	0.61	0.76	0.67	0.93	0.7	0.99	0.68	0.76	0.7		1.0	0.83
Net Working Capital	0.96	0.96	0.56	-0.92	0.95	0.83	0.65	0.72	0.63	0.94	0.67	1.0	0.71	0.73	0.69	1.0		0.81
Capital Stock	0.86	0.85	0.79	-0.76	0.83	0.88	0.5	0.79	0.74	0.81	0.73	0.81	0.59	0.79	0.85	0.83	0.81

Click cells to compare fundamentals

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Operating Income	-1.3 B	-1.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

UBER	Uber Technologies
APP	Applovin Corp
RYAAY	Ryanair Holdings PLC

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

BioNTech Operating Income from 2010 to 2025

Latest BioNTech's Operating Income Growth Pattern

BioNTech Operating Income Regression Statistics

BioNTech Operating Income History

Other Fundumenentals of BioNTech SE

BioNTech Operating Income component correlations

About BioNTech Financial Statements

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY